The Effect of Sublingual Nitroglycerin on Absolute Coronary Blood Flow

NCT ID: NCT06823843

Last Updated: 2025-03-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-07-01

Study Completion Date

2024-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to investigate the effect of sublingual nitroglycerin on absolute coronary blood flow in adult patients undergoing coronary angiography. The main questions it aims to answer are:

* Does sublingual nitroglycerin change absolute coronary blood flow compared to placebo?
* What is the effect of sublingual nitroglycerin on important cardioavascular parameters such as coronary pressure and resistance?

Researchers will compare the sublingual nitroglycerin group to the placebo group to see if nitroglycerin leads to significant changes in coronary blood flow and microvascular function.

Participants will:

* Receive either sublingual nitroglycerin or a placebo during coronary angiography.
* Undergo coronary blood flow measurements before and after the intervention using standardized assessment techniques.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

INTRODUCTION

Nitrates remain a key drug class in the management of angina pectoris due to their capacity to decrease myocardial oxygen demand. Their principle mechanism of action relates to the relaxation of vascular smooth muscle leading to vasodilation. Nitrates are predominately venodilators resulting in a decrease in cardiac preload, left ventricular diastolic pressure, and thus myocardial wall stress and subendocardial compression. However, at low doses, nitrates also trigger arterial and arteriolar dilatation with an eventual reduction in systemic vascular resistance and cardiac afterload at higher doses.

At the coronary level, the direct action of nitrates is thought to be almost exclusively restricted to the epicardial vessels with significant vasodilatation demonstrated in both normal and stenotic epicardial coronary arteries. Furthermore, in a canine model, nitrates have been shown to increase absolute coronary blood. The limited direct effect of nitrates on coronary microcirculation relates to the resistance of arterioles with a diameter \<100 μm to their action. However, coronary flow in these smaller vessels may be increased indirectly as decreased left ventricular end-diastolic pressure and wall stress induced by systemic venous dilatation has been shown to increase flow from the epicardium to endocardium.

Despite our understanding of the mechanisms behind the antianginal effects of nitrates, the quantification of their effect on absolute coronary flow has never been demonstrated in humans.

GOAL OF THE STUDY

In the present study, the investigators aim to use continuous thermodilution to asses the impact of sublingual nitroglycerin (NTG) on absolute coronary blood flow when compared with a placebo control.

DESIGN

This is an investigator-initiated, prospective, double-blinded randomised controlled study recruiting patients undergoing diagnostic coronary angiography for suspected angina pectoris from a single centre, and in whom coronary blood flow measurements are part of routine clinical practice, patients will be randomised between sublingual NTG and placebo.

OVERVIEW OF THE STUDY PROTOCOL

Critically, all recruited patients will have any pre-existing vasoactive medications stopped 24 hours before the protocol.

Upon completion of diagnostic coronary angiography, baseline and hyperemic, coronary pressures (Pd and Pa) and resting volumetric blood flow (Qrest) will be assessed by continuous thermodilution. These measurements necessitate the use of a pressure/temperature guidewire and a dedicated infusion catheter. They are performed routinely to evaluate the function of the microcirculation. The measurements are described in details hereunder (see paragraph 'Continuous thermodilution measurements').

During the measurement of resting flow, the patient will be randomised to either the intervention (2 puffs of sublingual NTG at a total dose of 800 µg) or a sublingual placebo by a research nurse. The research nurse will administer the sublingual spray with both the physicians and the patient blinded to patient randomisation. Once administered, continuous thermodilution will be continued for a further 7 minutes to permit enough time to capture any treatment effect as seen in the canine model. It is expected that the protocol, including recording of baseline values, will last \~10 minutes. The same protocol will then be repeated during hyperaemia.

The following parameters will be recorded/calculated at baseline as well as at 1, 3, 5, and 7 minutes post NTG administration, in order to capture the full effect of NTG on both coronary and systemic haemodynamics.

* Absolute coronary blood flow (Q)
* Microvascular resistance (Rµ)
* Epicardial resistance (Repi)
* Total resistance (Rtot)
* Aortic pressure (Pa)
* Distal coronary pressure (Pd)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Arterial Disease (CAD) Angina (Stable)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

2 puffs of sublingual saline

Group Type PLACEBO_COMPARATOR

Saline (NaCl 0,9 %) (placebo)

Intervention Type DRUG

2 puffs of sublingual saline

GTN

2 puffs for a total dose of 800 µg

Group Type EXPERIMENTAL

Glycerin trinitrate (GTN)

Intervention Type DRUG

2 sublingual puffs for a total dose of 800 µg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Glycerin trinitrate (GTN)

2 sublingual puffs for a total dose of 800 µg

Intervention Type DRUG

Saline (NaCl 0,9 %) (placebo)

2 puffs of sublingual saline

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Referred for invasive coronary angiography (ICA) for suspected coronary artery disease

Exclusion Criteria

* ≥1 severe stenosis (defined as a diameter stenosis \>70%)
* Clinical signs or symptoms of congestive heart failure
* Severe valvular heart disease requiring either surgical or percutaneous intervention
* History of coronary artery bypass grafting
* Tortuous coronary anatomy in which wire manipulation could be complex
* Significant arrhythmia
* Use of vasoactive medications within 24 hours of coronary angiography
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

VZW Cardiovascular Research Center Aalst

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

OLV Cardiovascular Center Aalst

Aalst, Flanders, Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

OLV2024/037; B1262024000004

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Endothelial Modulation for Angiogenic Therapy
NCT00134433 COMPLETED PHASE1/PHASE2